VEGFA and glioblastoma: Glioblastoma (GBM) is a very poor prognosis brain tumor, with a median survival of 16 months after treatment with temozolomide (TMZ), bevacizumab (Bev), a vascular endothelial growth factor (VEGF) inhibitor, and radiation1.